4.29 FCRL2 is a Distinct Marker of MT-CLL that Predicts Both Clinical Progression and Survival

FCRL2 is a Distinct Marker of MT-CLL that Predicts Both Clinical Progression and Survival Fu Jun Li, Alan Cantor, Mikhail A. Shakhmatov, Nicholas Chiorazzi, Randall S. Davis Divisions of Hematology/Oncology; Departments of Medicine, Microbiology, Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL; The Feinstein Institute for Medical Research, North Shore–LIJ Health System, Manhasset, NY; Departments of Cell Biology and of Medicine, North Shore University Hospital and Albert Einstein College of Medicine, NY